Suppr超能文献

BRAF V600E 突变和 microRNAs 有助于鉴别甲状腺乳头状癌恶性病变:组织和细针穿刺细胞学病例。

BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases.

机构信息

Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Life Sci. 2019 Apr 15;223:166-173. doi: 10.1016/j.lfs.2019.03.034. Epub 2019 Mar 16.

Abstract

AIMS

Mutations of BRAF oncogene are considered to contribute in the invasiveness and poor clinicopathologic features of papillary thyroid cancer (PTC). As a step towards understanding the underlying molecular mechanisms of this contribution, we aimed to examine the association of four microRNAs' (miR-222, -137, -214, -181b) levels with BRAFV600E and clinicopathological features in PTC tissues and fine needle aspiration (FNA) specimens.

METHODS

In total, 56 PTC and 27 benign with multinodular goiter tissue samples, 95 FNA samples, and B-CPAP and HEK293 cell lines were examined. BRAFV600E mutation was examined in PTC tissues and FNA samples. Expression of microRNAs was assessed by real-time quantitative reverse transcription-PCR.

KEY FINDINGS

The frequency of BRAFV600E in PTC tissues and FNA samples "suspicious for PTC" was 41.1 and 36.8%, respectively. MiR-222, -137, -214, and -181b were significantly upregulated in PTC tumors (P < 0.05) and in B-CPAP cell line (P < 0.001). In FNA, the expressions of miR-222, -181b and -214 were significantly elevated in patients suspected for PTC (P < 0.05), while there was no significant difference in miR-137. After adjustment for age and sex, miR-181b was associated with an increased risk of bearing BRAFV600E mutation (OR: 1.27; 95% CI: 1.01-1.61; P = 0.045) and risk of lymphovascular invasion (OR: 1.66; 95% CI: 1.01-2.72; P = 0.045); miR-137 was associated with the risk of larger tumor size (OR: 1.31; 95% CI: 1.04-1.65; P = 0.022); miR-222 was related to increase in extracapsular invasion (OR: 1.28; 95% CI: 1.04-1.57; P = 0.018).

SIGNIFICANCE

Upregulation of miR-222, -214 and -181b has been confirmed in PTC tumors, FNA samples and cell line. MiR-137 upregulation has been confirmed in PTC tumors and cell line, but not in FNA samples. MiR-222, -137 and -181b showed an association with the degree of malignancy in PTC tumors.

摘要

目的

BRAF 癌基因突变被认为有助于甲状腺乳头状癌(PTC)的侵袭性和不良临床病理特征。为了深入了解这种贡献的潜在分子机制,我们旨在研究四种 microRNAs(miR-222、-137、-214、-181b)水平与 PTC 组织和细针穿刺(FNA)标本中 BRAFV600E 及临床病理特征的关系。

方法

共检测 56 例 PTC 及 27 例伴多结节性甲状腺肿组织标本、95 例 FNA 样本、B-CPAP 和 HEK293 细胞系。在 PTC 组织和 FNA 样本中检测 BRAFV600E 突变。采用实时定量逆转录 PCR 检测 microRNAs 的表达。

主要发现

PTC 组织和 FNA 样本中 BRAFV600E 的频率分别为 41.1%和 36.8%。miR-222、-137、-214 和-181b 在 PTC 肿瘤(P<0.05)和 B-CPAP 细胞系(P<0.001)中均显著上调。在 FNA 中,疑似 PTC 患者的 miR-222、-181b 和-214 的表达显著升高(P<0.05),而 miR-137 则无显著差异。在调整年龄和性别后,miR-181b 与携带 BRAFV600E 突变的风险增加相关(OR:1.27;95%CI:1.01-1.61;P=0.045)和淋巴血管侵犯的风险(OR:1.66;95%CI:1.01-2.72;P=0.045);miR-137 与肿瘤较大有关(OR:1.31;95%CI:1.04-1.65;P=0.022);miR-222 与包膜外侵犯有关(OR:1.28;95%CI:1.04-1.57;P=0.018)。

意义

在 PTC 肿瘤、FNA 样本和细胞系中已证实 miR-222、-214 和-181b 的上调。在 PTC 肿瘤和细胞系中证实了 miR-137 的上调,但在 FNA 样本中未证实。miR-222、-137 和-181b 与 PTC 肿瘤的恶性程度有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验